US Clinical Trial NCT03950674

A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)  May 13, 2019

The MK-3475-189-Japan Extension Study will be identical to the global study (e.g. inclusion and exclusion criteria, study primary and secondary outcome measures and study procedures.

The MK-3475-189-Japan Extension Study has enrolled a total of 30 participants.

Parties

Investigators
Sponsors
Countries
JP
Keywords
Non-Small-Cell Lung Cancer (NSCLC) Non-Small-Cell Lung Carcinoma Programmed Cell Death-1 (PD1, PD-1) Programmed Death-Ligand 1 (PDL1, PD-L1)

JSON preview

Similar records

Title

Source:  NIH Last updated:  Jun 12, 2019

From ClinicalTrials.gov, a database of the U.S. National Institutes of Health, through its National Library of Medicine. This record may not reflect the most current and accurate biomedical/scientific data available from the NLM/NIH.